The ALDH4A1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the ALDH4A1 gene in a human lung adenocarcinoma background. This product comprises a heterogeneous pool of A-549 cells with targeted disruption of the ALDH4A1 locus, generated via CRISPR/Cas9-mediated gene editing. It provides researchers with a robust in vitro model to interrogate the consequences of abolished ALDH4A1 function without the limitations of clonal selection. The polyclonal format captures a broad spectrum of editing outcomes, enabling population-level analyses of metabolic and signaling perturbations following ALDH4A1 ablation. This knockout model is an essential tool for dissecting proline catabolism and its integration with central carbon metabolism in epithelial cancer cells.
Derived from a 58-year-old Caucasian male with lung carcinoma, the A-549 cell line is a widely used epithelial model for cancer biology and respiratory research. These cells retain key features of lung adenocarcinoma and are extensively characterized for studies on drug response, signal transduction, and metabolic adaptation. The A-549 background offers a relevant tumor context to examine how mitochondrial aldehyde dehydrogenase dysfunction alters cancer cell physiology. Its established use in metabolic flux analysis, viability assays, and oxidative stress profiling makes it an optimal host for investigating ALDH4A1-dependent pathways in neoplastic disease.
ALDH4A1 encodes a mitochondrial NAD+-dependent aldehyde dehydrogenase that catalyzes the oxidation of pyrroline-5-carboxylate (P5C) to glutamate, a reaction central to proline degradation and the interconnection of the TCA cycle with amino acid metabolism. The enzyme functions downstream of proline dehydrogenase (PRODH) and preceding glutamate dehydrogenase (GLUD1), forming a critical node in the arginine-proline metabolic axis. Its activity is tightly coupled to NAD+ cofactor availability and substrate flux from P5C, which is generated by P5C synthase and ornithine aminotransferase (OAT). Upstream, ALDH4A1 is regulated by proline availability and cellular stress signals, while its downstream products??glutamate and alpha-ketoglutarate??fuel TCA cycle anaplerosis, nucleotide biosynthesis, and reactive oxygen species (ROS) modulation. Loss of ALDH4A1 causes P5C accumulation, deprives the cell of glutamate-derived alpha-ketoglutarate, and may elevate oxidative stress through P5C-mediated ROS generation, thereby disrupting metabolic homeostasis.
In the A-549 adenocarcinoma system, ALDH4A1 knockout provides a physiologically relevant platform to dissect how proline catabolism impacts tumor metabolism. Lung cancer cells frequently engage in metabolic reprogramming to support proliferation, and proline has emerged as a key substrate under nutrient-limited conditions. Ablation of ALDH4A1 in this background allows systematic evaluation of how disrupted P5C-to-glutamate conversion affects TCA cycle anaplerosis, redox balance, and cellular biosynthetic capacity. This model also holds significance for inherited metabolic disorders such as hyperprolinemia type II, where ALDH4A1 deficiency leads to P5C accumulation and neurological complications, and it may offer mechanistic insights into cancer-associated metabolic vulnerabilities.
Typical research applications for this knockout model include metabolic flux analyses under proline-free conditions, high-resolution respirometry via Seahorse assays, and quantitative profiling of P5C and glutamate pools. Researchers can employ RT-qPCR or western blotting to confirm disruption of ALDH4A1 and monitor expression of related enzymes like PRODH and OAT. Cell viability and ROS detection assays further enable investigation of oxidative stress responses and metabolic dependencies. Additional uses encompass screening for small-molecule modulators of mitochondrial metabolism and studying the interplay between proline catabolism and TCA cycle dynamics in cancer. For further details on product specifications and experimental guidance, please contact Ascent Research.
